IMCR - CIK 0001671927
The table below shows Immunocore Holdings plc's cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q1 2025 | Q1 2024 | Q1 2023 |
|---|---|---|---|---|
| Operating cash flow | -$13.78M | $435.00K | -$4.59M | $10.54M |
| Capital expenditure | $1.78M | $298.00K | $430.00K | $3.00M |
| Investing cash flow | $4.22M | $9.70M | -$430.00K | -$3.00M |
| Dividends paid | - | - | - | - |
| Stock buybacks | - | - | - | - |
| Financing cash flow | $656.00K | $2.55M |
Immunocore Holdings plc reported operating cash flow of -$10.71M for fiscal year 2025. That is down 141.1% from $26.06M in fiscal 2024. Over the 5 fiscal years shown, operating cash flow grew from -$143.11M (FY 2021) to -$10.71M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $396.01M |
| $6.14M |